Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
2022-08-24 Sale | 2022-08-25 5:00 pm | 23andMe Holding Co. | ME | Hillan Kenneth J. Chief Therapeutics Officer | 8,753 | $3.64 | $31,861 | 196,083 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
2024-06-04 Option Award | 2024-06-06 4:23 pm | N/A 2034-06-03 | SANGAMO THERAPEUTICS INC | SGMO | Hillan Kenneth J. Director | 75,000 | $0 | 124,600 (Direct) | View |
2023-12-07 Option Award | 2023-12-08 5:17 pm | N/A 2033-12-06 | Zymeworks Inc. | ZYME | Hillan Kenneth J. Director | 37,000 | $0 | 37,000 (Direct) | View |
2023-06-05 Option Award | 2023-06-07 4:20 pm | N/A N/A | 23andMe Holding Co. | ME | Hillan Kenneth J. Chief Therapeutics Officer | 44,381 | $0 | 221,876 (Direct) | View |
2023-06-05 Tax Withholding | 2023-06-07 4:20 pm | N/A N/A | 23andMe Holding Co. | ME | Hillan Kenneth J. Chief Therapeutics Officer | 15,347 | $2.08 | 221,876 (Direct) | View |
2023-06-01 Option Award | 2023-06-05 4:48 pm | N/A 2033-05-31 | SANGAMO THERAPEUTICS INC | SGMO | Hillan Kenneth J. Director | 41,650 | $0 | 77,350 (Direct) | View |
2023-05-20 Tax Withholding | 2023-05-23 4:05 pm | N/A N/A | 23andMe Holding Co. | ME | Hillan Kenneth J. Chief Therapeutics Officer | 4,628 | $1.94 | 192,842 (Direct) | View |
2023-02-20 Tax Withholding | 2023-02-22 5:12 pm | N/A N/A | 23andMe Holding Co. | ME | Hillan Kenneth J. Chief Therapeutics Officer | 5,457 | $2.87 | 191,705 (Direct) | View |
2022-12-21 Option Award | 2022-12-23 7:00 pm | N/A 2032-12-20 | Zymeworks Inc. | ZYME | Hillan Kenneth J. Director | 25,000 | $0 | 25,000 (Direct) | View |
2022-11-20 Tax Withholding | 2022-11-22 4:11 pm | N/A N/A | 23andMe Holding Co. | ME | Hillan Kenneth J. Chief Therapeutics Officer | 4,628 | $2.99 | 197,162 (Direct) | View |
2022-08-20 Tax Withholding | 2022-08-22 6:12 pm | N/A N/A | 23andMe Holding Co. | ME | Hillan Kenneth J. Chief Therapeutics Officer | 4,628 | $3.33 | 204,836 (Direct) | View |
2022-06-01 Tax Withholding | 2022-06-02 4:26 pm | N/A N/A | 23andMe Holding Co. | ME | Hillan Kenneth J. Chief Therapeutics Officer | 4,627 | $2.82 | 209,464 (Direct) | View |
2022-02-25 Option Award | 2022-03-01 5:09 pm | N/A 2032-02-24 | SANGAMO THERAPEUTICS INC | SGMO | Hillan Kenneth J. Director | 37,500 | $0 | 60,700 (Direct) | View |
2022-02-09 Option Award | 2022-02-11 4:23 pm | N/A 2032-02-09 | 23andMe Holding Co. | ME | Hillan Kenneth J. Head of Therapeutics | 685,504 | $0 | 685,504 (Direct) | View |
Ownership | 2021-06-25 5:22 pm | N/A 2029-02-18 | 23andMe Holding Co. | ME | Hillan Kenneth J. Head of Therapeutics | 0 | $0 | 2,018,452 (Direct) | View |
2021-05-06 Option Award | 2021-05-07 8:45 pm | N/A 2031-05-05 | Zymeworks Inc. | ZYME | Hillan Kenneth J. Director | 9,000 | $0 | 9,000 (Direct) | View |
2021-02-25 Option Award | 2021-03-01 8:57 pm | N/A 2031-02-24 | SANGAMO THERAPEUTICS INC | SGMO | Hillan Kenneth J. Director | 24,600 | $0 | 39,600 (Direct) | View |
2020-09-09 Option Award | 2020-09-11 6:18 pm | N/A 2030-09-08 | SANGAMO THERAPEUTICS INC | SGMO | Hillan Kenneth J. Director | 45,000 | $0 | 45,000 (Direct) | View |
2020-05-08 Option Award | 2020-05-12 06:31 am | N/A 2030-05-07 | Zymeworks Inc. | ZYME | Hillan Kenneth J. Director | 9,000 | $0 | 9,000 (Direct) | View |